The Food and Drug Administration has approved the first seasonal flu vaccine in the United States built on messenger RNA technology, clearing it for adults 50 and older roughly two months before the 2026–2027 respiratory virus season typically begins. The shot, called mFLUSIVA, received full approval for adults 50 to 64 and accelerated approval for adults 65 and older, with the manufacturer required to complete an additional confirmatory trial in the older group.
For households, the practical question is simple: adults turning 50 or caring for an aging parent now have another option on the shelf when pharmacies begin fall flu clinics. Moderna says the vaccine will be available within a few weeks, according to NPR's report on the approval. It does not replace existing flu shots, and it is not authorized for anyone under 50.
The timing matters because influenza is not a mild season-to-season nuisance for older adults. CDC estimates the 2024-2025 flu season produced 51 million illnesses, 23 million medical visits, 710,000 hospitalizations and 45,000 deaths, and the agency classified that season as high severity in its end-of-season burden and severity summary. Those figures are the backdrop against which regulators weighed a new manufacturing platform.
A Faster Path from Strain Selection to Syringe
Conventional flu vaccines are built months in advance, many of them grown in chicken eggs, which locks manufacturers into strain choices made long before the season arrives. When circulating viruses drift after that point, protection can slip. Messenger RNA production skips the growth step, which is why vaccine researchers have argued the platform could shorten the gap between strain selection and finished doses, and why an mRNA vaccine could in principle be updated later in the year to better match a prevailing strain.
That flexibility is the central argument for the approval, not a claim of superior protection in every season. No such claim is part of the license.
Moderna framed the decision as a platform milestone. Chief executive Stéphane Bancel said in a statement that "Flu remains a significant public health challenge." That statement comes from the manufacturer, not an independent reviewer.
Evidence Behind the 27 Percent Figure
The approval rests on a large late-stage trial, and the headline number deserves precision. The pivotal study enrolled 40,805 adults aged 50 and older across 11 countries, with a median follow-up of six months. Moderna reported the phase 3 efficacy results as a relative vaccine efficacy of 26.6 percent, commonly rounded to about 27 percent, compared with a licensed standard-dose flu vaccine. In participants 65 and older, relative efficacy was 27.4 percent.
That is a relative comparison against another vaccine, not a measure of absolute protection. In the per-protocol analysis, influenza-like illness occurred in 2.0 percent of mRNA recipients and 2.8 percent of comparator recipients.
Side effects were more common than with conventional shots. Injection-site pain was reported by about 66 percent of mRNA recipients compared with roughly 30 percent of comparator recipients, and fatigue, headache, and muscle aches were also more frequent. Reactions were mostly mild to moderate and generally resolved within about two days. No new or serious safety signals were identified by the company or by FDA reviewers, and no cases of myocarditis or pericarditis occurred in the trial.
The evidence for adults 65 and older is the weaker part of the package, and regulators reflected that in the terms of the license. The comparator used in the trial was a standard-dose vaccine, while CDC preferentially recommends high-dose or adjuvanted products for that age group. The company agreed to a post-licensure study spanning two flu seasons. Until it reports, seniors do not have head-to-head evidence against the shots they are most likely to be offered today.
Availability, Insurance and Timing for Fall Shots
Doses are expected at select retailers in the coming weeks. Approval and coverage are separate questions. Whether a specific plan pays for this vaccine at zero cost sharing depends on downstream recommendations and plan design, so patients should confirm coverage with their insurer or pharmacy before the visit rather than assume parity with existing flu shots.
The regulatory path was contested. In February, the FDA issued a rare refusal-to-file letter declining to review the application, a decision made over the recommendation of career agency reviewers. The stated objection was the choice of comparator vaccine for adults 65 and older. The agency reversed course later that month after a high-priority meeting with the company, and an FDA advisory committee voted unanimously in June to support approval. That history is relevant context for readers following federal vaccine policy, but it does not change what the approved label now covers.
Older Adults and the Questions Worth Asking First
The people with the most at stake are adults 65 and older, adults 50 to 64 with chronic heart or lung disease or diabetes, and caregivers who share a household with someone in those groups. For them, the most useful step this month is not choosing a brand but confirming that a flu shot is scheduled at all.
Anyone weighing the new option can reasonably ask a clinician or pharmacist three things: whether a high-dose or adjuvanted vaccine is still the better fit given age and medical history, whether the more frequent short-term side effects are a concern given work or caregiving obligations, and when in the fall to schedule the dose. People with a history of severe allergic reaction to a vaccine component should raise that before booking.
No one should stop or change a prescribed medication because of a new vaccine approval, and no one should delay an available flu shot while waiting for a specific product to arrive. Federal advisers are expected to take up seasonal influenza recommendations before the season, and MedicalDaily will report those recommendations when they are issued.
The bottom line: a new tool now exists for adults 50 and older, the confirmatory evidence in the oldest group is still pending, and the practical decision for most households this fall remains getting vaccinated on time rather than holding out for a particular product.
Frequently Asked Questions
What exactly did the FDA approve? The agency approved mFLUSIVA, a seasonal influenza vaccine made with messenger RNA technology, for adults 50 and older. It is the first mRNA flu vaccine licensed in the United States.
Is it approved the same way for everyone 50 and older? No. Adults 50 to 64 received full approval. Adults 65 and older received accelerated approval, and the manufacturer must complete an additional study in that age group across two flu seasons.
Does 27 percent more effective mean it prevents 27 percent of flu? No. The trial measured a relative vaccine efficacy of 26.6 percent against a standard-dose comparator. It is a relative difference between two vaccines, not a measure of how much flu is prevented overall.
Are the side effects different from a regular flu shot? Trial participants reported more short-term reactions, including injection-site pain, fatigue, headache, and muscle aches. Most were mild to moderate and lasted about two days or less.
When will it be available and will insurance cover it? Doses are expected at some retailers within weeks. Coverage depends on your plan and on federal vaccine recommendations, so confirm with your insurer or pharmacy before your appointment.
Should older adults wait for this shot instead of getting the vaccine offered now? There is no evidence supporting a delay. Adults 65 and older should discuss with a clinician whether a high-dose or adjuvanted vaccine remains the better option for them.
Can children or adults under 50 get it? No. The license covers adults 50 and older only.
